Saroja Pharma Industries India Limited — Results, 04-08-2025: Reply to Clarification- Financial results

Saroja Pharma Industries India Ltd (#SAROJA) has announced its audited financial results for the half-year and full financial year ended March 31, 2025, which were approved by the Board on May 28, 2025.

For the full financial year (FY25), the company demonstrated strong performance:

* Total Income from Operations surged to ₹53.73 Cr, a notable increase from ₹40.86 Cr in FY24.

* Net Profit (PAT) grew to ₹1.03 Cr, up from ₹0.88 Cr in the previous year.

* Earnings Per Share (EPS) also saw a rise, reaching ₹2.57 compared to ₹2.49 in FY24.

Looking at the second half (H2 FY25) alone, Total Income from Operations was ₹35.00 Cr, with a Net Profit of ₹0.70 Cr and EPS of ₹1.74.

The balance sheet shows robust growth, with Total Assets expanding to ₹39.55 Cr as of March 31, 2025, up from ₹26.56 Cr last year. The company generated positive cash flow from operations, amounting to ₹1.15 Cr for FY25.

A significant portion of the IPO funds, ₹8.73 Cr out of ₹9.11 Cr, has been utilized for setting up a manufacturing unit and repaying unsecured loans, showing progress on strategic objectives. #Pharma #FinancialResults